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Abstract Atrioventricular block is classified as congeni-
tal if diagnosed in utero, at birth, or within the first
month of life. The pathophysiological process is believed
to be due to immune-mediated injury of the conduction
system, which occurs as a result of transplacental pas-
sage of maternal anti-SSA/Ro-SSB/La antibodies.
Childhood atrioventricular block is therefore diagnosed
between the first month and the 18th year of life.
Genetic variants in multiple genes have been described
to date in the pathogenesis of inherited progressive car-
diac conduction disorders. Indications and techniques of
cardiac pacing have also evolved to allow safe perma-
nent cardiac pacing in almost all patients, including
those with structural heart abnormalities.
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Conclusion: Early diagnosis and appropriate management
are critical inmany cases in order to prevent sudden death, and
this review critically assesses our current understanding of the
pathogenetic mechanisms, clinical course, and optimal man-
agement of congenital and childhood AV block.
What is Known:
• Prevalence of congenital heart block of 1 per 15,000 to 20,000
live births. AV block is defined as congenital if diagnosed in
utero, at birth, or within the first month of life, whereas
childhood AV block is diagnosed between the first month and
the 18th year of life. As a result of several different etiologies,
congenital and childhood atrioventricular block may occur in an
entirely structurally normal heart or in association with
concomitant congenital heart disease. Cardiac pacing is
indicated in symptomatic patients and has several prophylactic
indications in asymptomatic patients to prevent sudden death.
• Autoimmune, congenital AV block is associated with a high neonatal
mortality rate and development of dilated cardiomyopathy in 5 to 30 %
cases.
What is New:
• Several genes including SCN5A have been implicated in autosomal
dominant forms of familial progressive cardiac conduction disorders.
• Leadless pacemaker technology and gene therapy for biological
pacing are promising research fields. In utero percutaneous
pacing appears to be at high risk and needs further development
before it can be adopted into routine clinical practice. Cardiac
resynchronization therapy is of proven value in case of pacing-
induced cardiomyopathy.
Keywords Heart block . Pacemaker . Pathophysiology .
Outcomes . Congenital heart disease
Abbreviations
ACC American College of Cardiology
AHA American Heart Association
AV Atrioventricular
CHB Congenital heart block
CHD Congenital heart disease
DCM Dilated cardiomyopathy
ESC European Society of Cardiology
HRS Heart Rhythm Society
PCCD Progressive cardiac conduction disease
SVC Superior vena cava
Background
Cardiac conduction disorders are rare syndromes in neonates
and children [15, 64]. As a result of several different etiolo-
gies, it may occur in an entirely structurally normal heart or in
association with concomitant congenital heart disease (CHD).
In contrast to acquired atrioventricular (AV) conduction block,
congenital heart block (CHB)—identified in utero in normal
hearts—holds a significantly different prognosis with an
increased risk of late-onset cardiomyopathy. Fundamentally,
the pathogenesis is also disparate, driven by different maternal
clinical features and an increased risk of recurrence in future
pregnancies. For these reasons, AV block is classified as con-
genital if diagnosed in utero, at birth, or within the first month
of life. Therefore, childhood AV block is diagnosed between
the first month and the 18th year of life [15]. The estimated
prevalence of congenital heart block is 1 per 15,000–20,000
live births [64].
Atrioventricular conduction disorders in structurally
normal hearts
Immune-mediated AV block
Although some aspects remain to be clarified, pathophys-
iology, therapeutic approach, and long-term prognosis of
immune-mediated AV block have been extensively studied,
as it is one of the leading causes of congenital heart
blocks.
Pathophysiology Congenital AV block can be passively ac-
quired via an autoimmune process affecting the developing heart
due to the transplacental passage ofmaternal anti-Ro/SSA and/or
anti-La/SSB autoantibodies. Entering the fetal circulation, they
can directly bind L-type calcium channels on fetal
cardiomyocytes and significantly, but reversibly, inhibit the relat-
ed currents. However, in some cases, for unclear reasons, the
prolonged exposure to anti-Ro/SSA antibodies may induce cal-
cium channel internalization, in turn triggering a complex and
only in part mechanistically known perturbation of the cytoplas-
mic calciummetabolismwhich ultimately leads to apoptosis and
cell death, and then to local inflammation. If the process is not
stopped in this phase, the inflammatory damage proceeds, thus
eventually resulting in fibrosis and calcification of the cardiac
conduction system. This mechanistic sequence, also known as
Bcalcium channel hypothesis,^ is currently recognized as the
more attractive theory possible explaining the pathogenesis of
the disease [1, 90]. Maternal autoantibodies can be detected in
over 95 % of fetuses or newborns presenting with AV block,
namely congenital AV block [19]. In contrast, maternal autoan-
tibodies have been detected in only a minority of children, in
whom AV block was diagnosed beyond the neonatal period, a
different, distinct clinical entity [15, 34, 95]. However, some
isolated AV blocks diagnosed beyond the neonatal period are
also immune-mediated, even with late detection of maternal an-
ti-Ro/SSA autoantibodies [12]. This condition, emerging in
childhood or even in the adult age, represents a late progressive
congenital form of immune AV block with the late development
of a subclinical anti-Ro/SSA-induced congenital damage of the
conduction system, related to a not fully understood
autoantibody-independent worsening with age [51]. Between 2
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and 5 % of fetuses and infants whose mothers are autoantibody-
positive develop AV block, and the risk to subsequent pregnan-
cies is substantial (ranging between 12 and 25 %) in mothers
who have had a child with congenital AV block [16]. In up to a
third of infants with congenital AV block, a characterized auto-
immune disease, such as lupus, is present in the mother [16].
However, in the large majority of the cases, AV block occurs
in fetuses of healthy, silently anti-Ro/SSA antibodies-carrying
mothers. The diagnosis of mothers’ seropositivity is thus usually
made only after congenital AV block detection. In a recent pro-
spective study of 186 antibody-exposed fetuses and infants, it has
been demonstrated thatmothers of childrenwith cardiac involve-
ment were less likely to have had a connective tissue disease than
mothers of children without cardiac involvement [36].
Diagnosis of fetal AV block Fetal echocardiography is the
gold standard for the diagnosis of congenital AV block. All
M-mode and Doppler echocardiographic techniques rely on
the relationship between atrial and ventricular mechanical event
[30]. Although clinical applications of both fetal electrocardi-
ography and fetal magnetocardiography are more recent, these
two noninvasive tools are promising, being able to more
precisely diagnose fetal arrhythmias and conduction disorders
[23, 103]. Complete fetal AV block develops during gestational
weeks 16 to 24, although a later onset of the phenomenon up to
gestational week 34 has been described [2, 72].
Clinical course CHB derived from an autoimmune process is
associated with a high neonatal mortality rate [16, 37]. The
estimated overall mortality without pacing is estimated to be
around 8–16 % in infants and half as much in children and
adults [37, 65]. Interestingly, cardiac dilatation and impaired
ventricular function can develop as long-term sequelae in those
who forego pacing and those who are permanently paced.
Without pacing support, it appears that the slow heart rates
and associated higher stroke volumes probably drive this pro-
cess [65]. But with pacing, the current hypothesis centers on a
pacing-induced cardiomyopathy. Globally, the prevalence of
dilated cardiomyopathy (DCM) in CHB ranges from 5 to
30 % [66, 91, 94]. Various pathophysiological processes, in-
cluding transient myocarditis or immune-mediated myocardial
injury, have been proposed to explain the development of ven-
tricular dilatation and dysfunction. Late-onset dilated cardio-
myopathy in patients with complete heart block may be a se-
quela of in utero autoimmunemyocarditis or due to its postnatal
reactivation [95]. Right and left ventricular endocardial
fibroelastosis and fibrosis have been observed at autopsy.
These observations were not limited to the conduction system
and involved the working ventricular myocardium. The detri-
mental effects of maternal antibodies directed against fetal car-
diac tissue provided evidence in favor of the immunopatholog-
ic role played by the maternal autoantibodies in congenital AV
block. In view of the myocardial dystrophic changes and
adverse remodeling caused by ventricular desynchronization,
right ventricular pacing has been suggested as an important
cause of DCM [66, 91, 94]. In some patients, the discontinua-
tion of right ventricular pacing or upgrade to cardiac
resynchronization therapy alone normalized systolic function,
which would not be expected to occur if ongoing myocarditis
or other autoimmune factors were the only cause of DCM [13,
39, 67].
Inherited AV block
Inherited progressive cardiac conduction disease (PCCD) is
diagnosed in patients less than 50 years of age with an unex-
plained progressive conduction abnormality but with an other-
wise structurally normal heart, especially if there is a family
history of PCCD. This excludes the skeletal myopathies and
muscular dystrophies, given the recognized impact of such
progressive disorders on the cardiac muscle [70]. Since the
publication of Morquio’s first report of familial segregation
of heart blocks in 1901, major advances have been made in
our understanding of the clinical, genetic, and molecular char-
acteristics of inherited PCCD. Familial clustering of PCCD of
unknown cause, including congenital AV block, has been re-
ported. Published pedigrees have shown an autosomal domi-
nant inheritance with incomplete penetrance and variable ex-
pressivity [32, 56]. Inherited PCCD in structurally normal
hearts presents as a primary electrical disease and has been
linked to genetic variants in the ion channel genes SCN5A,
SCN1B, SCN10A, TRPM4, and KCNK17 as well as in genes
coding for cardiac connexin proteins [8, 58, 77]. Moreover,
SCN5Amutation carriers tend to exhibit Bcardiac sodium chan-
nelopathy overlap syndrome,^ with overlapping clinical man-
ifestations of the distinct SCN5A-related syndromes such as
longQTsyndrome type 3 or Brugada syndrome, and an altered
cardiac conduction in many cases [44]. It is now clear that
complex pathophysiological processes involving many genes
and gene networks may lead to the occurrence of atrioventric-
ular and intraventricular block. It is likely that only a small
fraction of these genetic defects have been identified, and it
is likely that genetic tests could help in the future to better
determine the risk of progression of a conduction defect and
hence determine the best timing for pacemaker implantation.
Apparently Bidiopathic^ AV block
Rarely, AV block of unknown origin appears during childhood,
in the absence of maternal antibodies, structural heart disease,
or other overt causes. Scientific literature is scarce regarding the
etiology and the clinical course of these patients with apparently
idiopathic heart block. In the first large-scale study, looking for
heritability of pediatric idiopathic heart block in a French na-
tionwide cohort, Baruteau et al. observed a high degree of in-
heritance and a strong genetic background in the pathogenesis
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of congenital and childhood nonimmune isolated AV block [9,
10]. Thus, familial screening should be considered and may
provide strong arguments for heritability, even in patients where
the disorder appears to be sporadic and idiopathic.
Atrioventricular conduction disorders in association
with congenital heart disease
Native
Recent genetic findings suggest that approximately 10 % of
sporadic CHD may have de novo mutations that significantly
contribute to the disease process [101]. Mutations in genes
encoding for transcription factors critical for cardiac chamber
formation, endocardial cushion remodeling, and conduction
system development, like NKX2.5 and Tbx5, may lead to
PCCD associated with CHD [61]. Numerous mutations in
NKX2.5 have been reported with various CHD phenotypes,
such as secundum atrial septal defect, tetralogy of Fallot,
truncus arteriosus, double-outlet right ventricle, L-
transposition of great arteries, interrupted aortic arch, ventricu-
lar noncompaction, and hypoplastic left heart, with or without
conduction disorders [62, 78]. Tbx5 mutations are responsible
for Holt-Oram syndrome, an autosomal dominant inherited
disease characterized by radial ray upper limb abnormalities,
cardiac septation defects, and various degrees of cardiac con-
duction disorders whichmay occur even in the absence of overt
structural heart disease [6].
Kearns-Sayre syndrome is amitochondrial disorder character-
ized by onset before the age of 20, progressive external
ophthalmoplegia, and pigmentary retinopathy, accompanied by
either cardiac conduction defects, elevated cerebrospinal fluid
protein, or cerebellar ataxia. Fifty percent of affected patients
develop cardiac complications, the most common of them being
conduction disease whichmay progress to complete AV block or
bradycardia-related polymorphic ventricular tachycardia [42].
Heart block affects one third of fetuses with heterotaxy
syndrome and left atrial isomerism, being a primary risk factor
for perinatal mortality [88]. The most common CHD associ-
ated with conduction disorders is L-transposition of the great
arteries [97]. Abnormal development of the central fibrous
body with lack of union between AV node and AV bundle
or formation of the conduction tissue from the anterior endo-
cardium were suggested to be the possible causes of block
seen in L-transposition [3]. The lifelong risk for complete
block in these patients is roughly 1 % annually and roughly
50 % to develop heart block spontaneously by age 50 [97].
Postoperative
Following CHD surgery, any degree of AV block may be seen
(Figs. 1 and 2). A retrospective multicenter study recently
evaluated incidence of postoperative complete heart block in
children undergoing congenital heart surgery [53]. Among
103,616 surgeries from 45 US tertiary care hospitals, the inci-
dence of complete heart block requiring pacemaker placement
was low (1.2 %), mainly associated with mitral valve repair or
replacement (3.7 %), aortic valve repair or replacement
(2.7 %), atrioventricular canal surgery (1.9 %), and ventricular
septal defect (VSD) surgery (1.8 %). However, these patients
incurred longer hospital stay and had higher mortality even
after accounting for heart surgery complexity.
In roughly one third of the cases of postoperative complete
heart block, AV conduction does not recover and those pa-
tients should undergo pacemaker implantation. Permanent
pacemaker implantation should be considered in all patients
who have postoperative high-grade AV block following CHD
surgery that exceeds 7–10 days, even in the setting of a narrow
QRS escape rate [14, 26]. During this period, temporary pac-
ing wires may be necessary to maintain adequate chronotropy.
Postoperative heart block has also been rarely reported in pa-
tients who had been previously discharged from the hospital
with normal AV conduction after open-heart surgery. Close
and continued follow-up of postoperative CHD surgical cases,
particularly VSD, is necessary due to the risk of possible pro-
gression of block over time [54].
Atrioventricular conduction disorders in association
with acquired heart disease
AV block in the young can also be derived from a wide vari-
ety of causes such as surgical or catheterization-induced
trauma, coronary artery disease, acute or chronic infectious
processes, myocarditis, hypersensitivity cardiomyopathy,
metabolic abnormalities, hypothyroidism, infiltrative pro-
cesses, or through a pathological neurocardiogenic mecha-
nism [7]. Even if temporary pacing might be required in un-
stable patients with Lyme carditis, complete heart block is
usually reversible with appropriate antibiotics [28]. Chagas
disease is an endemic disease in most Latin American coun-
tries, and around one third of affected patients develop car-
diac conduction disorders requiring pacemaker implantation
[4]. Incidence of catheterization-induced heart block was
recently evaluated at 2.2 %, with a high rate of recovery
following a similar course to that of postsurgical heart block
[57]. Some interventional procedures, such as device closure
of perimembranous VSD and catheter ablation of AV nodal
reentrant tachycardia or parahissian accessory pathways,
carry a risk of permanent heart block [49, 100, 102]. The
incidence of AV node dysfunction is apparently higher in
patients with Kawasaki disease, possibly caused bymyocar-
ditis or an abnormal microcirculation in the AV node artery.
Acute rheumatic carditis must also be kept in mind in the
diagnostic work-up of patients with AV conduction disorder
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in association with acquired heart disease, particularly when
it occurs in pediatric patients;Most cases are reversible first-
or second-degree AV blocks. Although a rare and usually
transient finding during acute rheumatic fever, complete
AV block may lead to symptoms and need a specific
treatment.
Fig. 1 Complete atrioventricular block: unpaced electrocardiogram. Postoperative 12-lead electrocardiogram demonstrating complete heart block with
slow ventricular escape rate, after tricuspid valve replacement
Fig. 2 Complete atrioventricular block: paced electrocardiogram. Twelve-lead electrocardiogram from patient demonstrating atrial sensed ventricular
paced rhythm
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Management
Treatment options during fetal life
Left untreated, congenital AV block is associated with a fetal
and neonatal mortality ranging between 14 and 34 % [76].
Fetal hydrops and ventricular escape rates <55 bpm have been
identified as risk factors for mortality [54, 55]. Transplacental
treatment options are not consensual. Dexamethasone use
may significantly lower fetal mortality [38], but its adminis-
tration remains controversial because of its potential side ef-
fects for both mother and fetus, especially potential fetal neu-
rological development impairment [68]. Maternal administra-
tion of terbutaline has also been reported, used alone or in
addition to dexamethasone [20]. Although largely controver-
sial, prenatal treatment may also include intravenous immu-
noglobulins and plasmapheresis, used alone or together in
combination with steroids [31, 75].
Using the currently available techniques, in utero percutane-
ous pacing appears to be at high risk, with fetal deaths occur-
ring within a few hours of the procedure in a high proportion of
cases [5]. Further studies would be required to improve our
understanding of the natural history of congenital AV block
in order to identify more accurately the fetuses at highest risk.
Development in the techniques and technologies available to
deliver in utero pacing would also be required before this treat-
ment can be adopted into routine clinical practice.
Postnatal medical therapy
Pharmacological therapy has a distinct role in the acute man-
agement of severe bradycardia (whether sinus- or AV nodal-
related) and should typically be carried out alongside parallel
efforts to arrange for transcutaneous pacing and temporary
cardiac pacing in order to prevent from sudden cardiac death
[48]. Intravenous isoproterenol, atropine, epinephrine, and do-
pamine are all recommended [48]. Beyond the acute manage-
ment in this context, no medication is proven to improve
chronic sinus- and AV nodal function. It is crucial, however,
to recognize the potential for medications to compromise car-
diac conduction, especially considering the atypical antihyper-
tensive and antipsychotic agents, in addition to the AV nodal
blocking agents they may contain. Monitoring of children
who do not require neonatal pacing is based on 24-h Holter
ECG and transthoracic echocardiography that should be per-
formed frequently.
Permanent pacemaker implantation
The indications for permanent pacing in children or adults
with CHD are similar to those recommended in acquired heart
disease, yet there are important differences in the approach
based primarily on anatomy and somatic growth.
Indications In essence, every symptomatic, non-reversible
AV node disease requires permanent pacemaker implantation
[14, 26]. Pacing must also be considered in asymptomatic
high degree AV blocks with specific risk conditions. Recent
indications for cardiac pacing in children and CHD patients
are summarized in Table 1. Although historical series of iso-
lated congenital AV block reported a high incidence of unpre-
dictable Stokes-Adams attacks and a highmortality associated
with the first attack [2, 18], latest studies performed in our era
of pediatric cardiac pacing showed that prophylactic pacing,
as currently recommended [44, 45], is associated with strong
reduction in the morbidity and mortality due to Stokes-Adams
attacks [32].
Endocardial versus epicardial deviceAlthough pacing indi-
cations are clearly defined, whether an endocardial versus an
epicardial system is preferred remains to be clarified [26, 48,
96]. The large population of adult paced patients allows for
surgical practices to be studied more effectively and lead to
evidence-based transitions in patient care. Meanwhile, the
smaller volume of paced pediatric patients does not provide
enough information and clinical decisions based on faith,
opinion, experience, and some retrospective data. Within
those limitations, there is a general consensus that the smallest
infants are best served with epicardial pacing systems, with a
cutoff weight around 15–20 kg [26, 98]. Epicardial leads are
more likely to fracture and are prone to exit block, and im-
plantation requires a major operation that is accompanied by
the inherent risks and need for perioperative support [89]
(Fig. 3). However, many groups standardly use epicardial
pacing in infants and young children and argue that endocar-
dial systems may carry a significant risk of venous thrombosis
in infants, which can result in loss of venous access in the
future, leading to a more complicated lead revision later in
the patient’s life [18, 29, 50]. Up to a 19 % transvenous
lead-related failure rate has been reported by others who
choose the endocardial approach [80]. Extraction of aban-
doned transvenous leads in the pediatric population is also
problematic, and optimal lead management still remains to
be defined [17, 60]. On the other hand, there is a global trend
towards using endocardial leads in younger patients and some
institutions actively implant transvenous leads in children
weighing less than 15 kg [43, 63, 73, 79, 83, 85]. It has been
shown that an 80-mm right atrial lead loop will allow 6 to
12 years (mean, 8 years) of growth in infants and children
without the need for reoperation to adjust lead length [33]
(Figs. 4, 5 and 6). Long-term follow-up demonstrates that
the longevity of an endocardial system exceeds that of its
epicardial counterpart [89, 98], also an important consider-
ation in patients who will be exposed to the cumulative burden
of repeated lead and device reimplantation. Despite growing
experience, endocardial implantation is not universally ac-
cepted. Most publications reporting results of transvenous
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pacing in infants and young children are from small and/or
older studies [33, 40, 43, 55], so that long-term follow-up data
from large patient populations should still be clarified.
Route of pacing Gaining access to the chamber requiring
pacing is another central hurdle, frequently challenging in this
patient group, and thereby commonly dictating the route of
pacing but also highlighting why a detailed surgical history is
vital. Modern-day pacemaker implantation is therefore suit-
ably complemented by adjunctive CT or MR angiography,
indicating whether an endocardial system is possible, and also
providing a map for coronary sinus lead placement. For com-
plex CHD patients with prior operative intervention and
whose surgical reports are not available, venography at the
time of the procedure is recommended [14, 26]. Absolute
contraindications to conventional transvenous, endocardial
lead placement include occlusion of the superior vena cava
(SVC) (bidirectional cavopulmonary anastomosis/Glenn),
extra-cardiac Fontan procedures, baffle thrombosis, and se-
vere baffle stenosis. Attempts to access the subpulmonic ven-
tricle by crossing a mechanical atrioventricular valve should
also absolutely be avoided [27]. In this situation, coronary
sinus lead placement can potentially be used for ventricular
pacing.
In patients in whom a conventional transvenous approach
via the SVC is not possible, femoral and transhepatic lead
implantation can also be considered. Femoral techniques have
been reported predominantly in children, suggesting this is a
viable alternative with issues related primarily to the stability
of the atrial lead and discomfort from the abdominally placed
generator [59]. This approach does entail a higher incidence of
lead failure given the additional mechanical stress associated
with hip flexion. Transhepatic implants have also only been
reported in children and acutely present the additional risks of
Table 1 Pacing indications in children and patients with congenital heart disease
ESC guidelines ACCF/AHA/HRS guidelines
Congenital AV block
Symptomatic advanced second- or third-degree AV block Class I, level C Class I, level C
Asymptomatic high degree AV block with ventricular dysfunction Class I, level C Class I, level B
Asymptomatic high degree AV block with prolonged QTc interval Class I, level C –
Asymptomatic high degree AV block with complex ventricular ectopy Class I, level C Class I, level B
Asymptomatic high degree AV block with wide QRS escape rhythm Class I, level C Class I, level B
Asymptomatic high degree AV block with abrupt ventricular pauses
>threefold the basic cycle length
Class I, level C Class IIa, level B
Asymptomatic third-degree AV block in the infant with a ventricular rate
<55 bpm or with CHD and a ventricular rate <70 bpm
– Class I, level C
Third-degree AV block beyond the first year of life with an average heart
rate <50 bpm
– Class IIa, level B
Asymptomatic high degree AV block with a ventricular rate <50 bpm Class I, level C –
Third-degree AV block beyond the first year of life with symptoms due
to chronotropic incompetence
– Class IIa, level B
High degree AV block in asymptomatic children/adolescents in absence
of the above risk conditions
Class IIb, level C Class IIb, level B
Asymptomatic type I second-degree AV block – Class III, level C
Postoperative AV block
Postoperative advanced second- or third-degree AV block that persists
>7 days after cardiac surgery (10 days in ESC guidelines)
Class I, level B Class I, level B
Transient postoperative third-degree AV block that reverts to sinus rhythm
with residual bifascicular block
Class IIa, level C Class IIb, level C
Unexplained syncope in the patient with prior CHD surgery complicated
by transient complete heart block with residual fascicular block
– Class IIa, level B
Transient postoperative AV block with return of normal AV conduction
in the otherwise asymptomatic patient
– Class III, level B
Asymptomatic postoperative bifascicular block with/without first-degree
AV block in the absence of prior transient complete AV block
– Class III, level C
Levels of evidence are classified in Blevel A^ if data are derived from multiple randomized clinical trials or meta-analyses, Blevel B^ if data are derived
from a single randomized clinical trial or large non-randomized studies, and Blevel C^ if there is a consensus of opinion of the experts and/or if data are
derived from small studies, retrospective studies, or registries. Recommendations are listed according to the commonly used class I, IIa, IIb, and III
classification and the corresponding language: Bis recommended^ for a class I recommendation; Bcan be useful^ for a class IIa recommendation; Bmay be
considered^ to signify a class IIb recommendation; and Bshould not^ or Bis not recommended^ for a class III recommendation. ESC guidelines: reference
[44]; ACCF/AHA/HRS guidelines: reference [45]
AV atrioventricular, CHD congenital heart disease
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intraabdominal or intracapsular hemorrhage, and long-term
outcomes remain uncertain [25].
Placing leads in patients with prior atrial switch operations
(Mustard/Senning) must be handled with utmost care, given
the frequency of baffle leaks in this group [47]. Pre-emptive
covered stent implantation or even open repair should be con-
sidered given the risk of thromboembolism across these veno-
systemic shunts. A transcatheter approach is utilized for leak
closure but can also be applied for dilatation of a narrowed
baffle that would otherwise be occluded by transvenous lead
implantation [11, 24].
Thromboembolism Any patient with an intracardiac shunt is
at higher risk for thrombus formation on transvenous pacing
leads and subsequent systemic thromboembolic complications
[21, 45]. Pre-emptive transesophageal echocardiography with
bubble injections is therefore critical, and if any shunt is seen,
the approach should be modified. If the shunt can be closed,
either via an open approach or using a percutaneous approach,
then this should be undertaken before endocardial leads are
placed or alternatively an epicardial device should be im-
planted. It remains unclear how to exactly manage patients with
a small shunt at an atrial level across a patent foramen ovale and
further studies would be needed to develop recommendations
[21]. It is also vital to recognize that the patients with a classic
Fontan operation frequently have very large atria and slow flow
through their neo-chamber. Thus, it is not uncommon for large
thrombi with a potential for pulmonary thromboembolism to
develop on transvenous leads. And although this does not pres-
ent an absolute contraindication [69, 87], it does need to be
carefully considered and weighed against the risks of epicardial
lead placement. Long-term oral anticoagulation does also need
to be accordingly considered in this group.
Lead position The pacing site of the ventricular leads is a critical
issue, as it has a major impact on left ventricular mechanical
synchrony, efficiency, and pump function in childrenwho require
lifelong pacing. The right ventricular apex has been the most
used pacing site, because it is easily accessible transvenously
and provides a stable lead position with a low dislodgment rate.
However, long-term right ventricular apical pacing induces an
iatrogenic left bundle branch block and can lead to pacing-
induced cardiomyopathy with left ventricular dilation and both
Fig. 3 Permanent pacemaker with epicardial leads (VVI pacing)
Fig. 4 Permanent pacemaker with transvenous leads. Growth and change
in a loop of an endocardial lead. A 4-year-old boy with childhood isolated
nonimmune atrioventricular block underwent pacemaker implantation
using a transvenous lead. Radiographs at 4 years of age (a, VVI pacing),
6 years later (b, DDD pacing), and 9 years later (c, DDD pacing). Note the
change in the loop of the lead as the child grows
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systolic and diastolic left ventricular dysfunction, for both endo-
cardial and epicardial leads [46, 67, 86, 91, 99]. There is early
encouraging data that suggest improved overall hemodynamics
and ventricular function by cardiac resynchronization therapy
with single-site left ventricular pacing via the coronary sinus in
this group [41]. Until further supportive evidence is accrued, it is
important for the implanter and clinician to consider this ap-
proach in any patient whose ejection fraction is suboptimal.
However, detrimental effects of the right ventricular apical
pacing led to the reassessment of traditional approaches and to
the research of alternative pacing sites, in order to get to more
physiological pattern of ventricular activation. Although be-
ing theoretically the best technique, direct His-Bundle pacing
and paraHisian cardiac pacing remain complex and associated
with higher pacing thresholds are required, causing accelerat-
ed battery depletion [93]. Right ventricular septal pacing is a
good alternative, technically easy and maintaining a lower
pacing threshold [22]. By preserving septal to lateral left ven-
tricular synchrony and systolic function, left ventricular apical
and midlateral wall pacingmay be the preferred pacing site for
epicardial leads in the young [41, 81].
Mode of pacing A five-letter international code describes
pacemaker function, three letters being in common usage:
the first letter is the chamber paced (A = atrium; V = ventricle;
D = dual, namely both A and V; O = none), the second letter is
the chamber sensed and the third letter describes the algorithm
used to integrate pacing and sensing functions. Most of chil-
dren and teenagers will benefit from a dual-chamber pacing
(DDD), allowing AV synchrony that is important to maintain
ventricular filling and stroke volume [89, 96]. In infants with
complete AV block and normal sinus node function, a single-
chamber ventricular pacing (VVI or VDD) should be selected,
because it requires only a unique lead (uni- or bipolar) thus
reducing the risk of venous occlusion [89, 96].
In patients with conduction system disease undergoing
pacemaker implantation, coexistent reentrant atrial tachycar-
dias are common. Therefore, the implantation of devices with
atrial antitachycardia pacing capability is reasonable [84].
This approach is more common as an adjunct to maze proce-
dures and in conjunction with antiarrhythmic therapy [92].
Perspectives To overcome the potential short- and long-term
complications related to transvenous leads and subcutaneous
pulse generators, new technologies enabling leadless cardiac
Fig. 5 Cardiac resynchronization therapy with epicardial leads. A 5-year-
old boy who underwent a neonatal Ross procedure had postoperative
complete heart block and left ventricular dysfunction. He was implanted
with epicardial multisite pacing with right atrial, right ventricular (a and b,
black star), and left ventricular (a and b, black arrow) leads. Biventricular
pacing allow shortening of the paced QRS (c, 224 ms) compared with right
ventricular pacing alone (d, 128 ms)
Fig. 6 Cardiac resynchronization therapy with transvenous leads. A 14-
year-old boy with dilated cardiomyopathy and left ventricular dysfunction,
second-degree AV block, and an episode of ventricular fibrillation had
implantation of a biventricular implantable cardioverter-defibrillator with
a transvenous right ventricular lead (a and b, black star) and a transvenous
left ventricular lead into the coronary sinus (a and b, black arrow)
Eur J Pediatr
stimulation have been developed and proved to be applicable
and safe in experimental models and in some small human
studies [52, 71, 82]. These ultrasound or induction technolo-
gies, based on leadless pacemakers, could be used to provide
cardiac stimulation from the endocardium at selected sites. The
absence of a transvenous lead and subcutaneous pulse genera-
tor could represent a paradigm shift in cardiac pacing. Future
studies will need to address the safety/efficacy of alternate-site
RV and LV pacing and the long-term outcomes of these new
approaches. Although the continued development and success
of electronic pacing are impressive, gene therapy for biological
pacing is also a promising research field. This approach might
offer an alternative treatment for pacemaker-related infections
in the future, with right ventricular intramyocardial injection of
an adenoviral construct whose duration of effect is temporary,
until such time as the infection is adequately treated and a new
permanent pacemaker can be inserted [35, 74].
Conclusion
Although rare, congenital and childhood AV block is important
treatable cause of morbidity and mortality in the young. This
review crystallizes our contemporary understanding and man-
agement strategies, highlighting the ongoing investigation in all
aspects of care related to this complex group of disorders.
Much work is needed, especially with regards to the antenatal
detection and treatment of congenital AV block, and on a ge-
netic level, and it is evident that as new insights are gleaned,
management strategies continue to evolve. Despite the many
different etiologies, eachwith specific management and distinct
outcomes, these patients can do well with a careful, considered
approach to the diagnostic evaluation and management plan.
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